Lana Dinic
Director, Project and Portfolio Management, Pioneering Medicines
Lana joined Pioneering Medicines in 2020 and is responsible for providing scientific and business insights into the overall portfolio strategy as well as project management of key programs.
Before joining Pioneering Medicines, Lana worked at Kintai Therapeutics (now Senda Biosciences), a Flagship company, where she was Chief of Staff to the CEO, driving critical operational and strategic initiatives. Prior to Kintai, Lana spent seven years at L.E.K. Consulting in their Boston and London offices. There she led international teams defining and executing corporate strategies, evaluating market opportunities and commercial strategy, and optimizing operations for pharmaceutical and biotech clients. In addition, she established a broad range of initiatives to integrate the Global Life Sciences practice and developed best practices to advance the firm鈥檚 capabilities.
Lana earned her Ph.D. in Dr. Phyllis Kanki鈥檚 Lab in the Department of Immunology and Infectious Diseases at Harvard. While there, she worked with the Harvard-President's Emergency Plan for AIDS Relief program, and had the opportunity to help build a molecular diagnostics lab and train clinical laboratory scientists in Nigeria and Tanzania. Her graduate thesis focused on tuberculosis drug resistance and mycobacterial disease diversity in HIV patients in Nigeria.
Prior to graduate school Lana did research on RNA interference in the Tuschl Lab at Rockefeller University. She holds a B.A. in Biochemistry from Mount Holyoke College.
